Clinical Research Directory

Inclusion Criteria: * 18 to 70 years of age. * Body Mass Index (BMI) ≥ 25 at screening. * BMI ≥ 23 for Asian participants at screening. * Stable body weight (approximately 5% or less gain or loss) during the 4-week run-in period, unless the study doctor determines otherwise. * Stable dose of weekly GLP-1RA. * Stable gastrointestinal (GI) tolerability. * Contraception for females. * Stable for 3 months if obstructive sleep apnea (OSA), hypertension, hyperlipidemia, and/or hypothyroidism. * Willingness to follow trial procedures for the duration of the trial. Exclusion Criteria: * Type 1/Type 2 diabetes mellitus (DM). * Obesity induced by other endocrine disorder (ex: Cushing's syndrome). * History of malignancy in the last 5 tears except for nonmelanoma skin cancers, cervical, or breast ductal carcinoma in situ. * Acute \& chronic pancreatitis within 1 year. * Uncontrolled thyroid disease. * Gastroparesis or gastric outlet obstruction. * Surgery for obesity in the last 6 months. * Heart attack within 3 months. * History of ischemic optic neuropathy. * Positive HIV or certain positive Hepatitis B or hepatitis C. * Current use of compounded weekly GLP-1RA. * Previous participation in Maridebart cafraglutide trial. * Alcohol or drug abuse. * Pregnancy, breastfeeding, or planning to breastfeed.